1-18 of 18
C. Patrick Reynolds
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler, Wayne Blosser, Alle B. VanWye, Jennifer R. Stephens, Philip W. Iversen, Aimee Bence Lin, Richard P. Beckmann, Kateryna Krytska, Kristina A. Cole, John M. Maris, Douglas S. Hawkins, Brian P. Rubin, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Stephen W. Erickson, Beverly A. Teicher, Malcolm A. Smith, Louis F. Stancato
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2278–2289.
https://doi.org/10.1158/1078-0432.CCR-18-2728
Published: 01 April 2019
View article titled, Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Open the PDF for Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

Ann M. Mohrbacher, Allen S. Yang, Susan Groshen, Shivaani Kummar, Martin E. Gutierrez, Min H. Kang, Denice Tsao-Wei, C. Patrick Reynolds, Edward M. Newman, Barry J. Maurer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (16): 4550–4555.
https://doi.org/10.1158/1078-0432.CCR-17-0234
Published: 14 August 2017
View article titled, Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
Open the PDF for Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial in another window
Includes: Supplementary data
Journal Articles

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma

Kateryna Krytska, Hannah T. Ryles, Renata Sano, Pichai Raman, Nicole R. Infarinato, Theodore D. Hansel, Monish R. Makena, Michael M. Song, C. Patrick Reynolds, Yael P. Mossé
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 948–960.
https://doi.org/10.1158/1078-0432.CCR-15-0379
Published: 14 February 2016
View article titled, Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Open the PDF for Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

Connor P. Hall, C. Patrick Reynolds, Min H. Kang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (3): 621–632.
https://doi.org/10.1158/1078-0432.CCR-15-0114
Published: 31 January 2016
View article titled, Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Open the PDF for Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 in another window
Includes: Supplementary data
Journal Articles

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1139–1150.
https://doi.org/10.1158/1078-0432.CCR-14-1882
Published: 01 March 2015
View article titled, Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <em>SLFN11</em> Expression
Open the PDF for Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High <em>SLFN11</em> Expression in another window
Includes: Supplementary data
Journal Articles

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Hernan Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 819–832.
https://doi.org/10.1158/1078-0432.CCR-14-2572
Published: 16 February 2015
View article titled, Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Open the PDF for Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma

Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Maldonado, Yves A. DeClerck, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 7093–7104.
https://doi.org/10.1158/1078-0432.CCR-11-0578
Published: 14 November 2011
View article titled, Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma
Open the PDF for Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group

Judith G. Villablanca, Wendy B. London, Arlene Naranjo, Patrick McGrady, Matthew M. Ames, Joel M. Reid, Renee M. McGovern, Sarah A. Buhrow, Hollie Jackson, Enno Stranzinger, Brenda J. Kitchen, Paul M. Sondel, Marguerite T. Parisi, Barry Shulkin, Gregory A. Yanik, Susan L. Cohn, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6858–6866.
https://doi.org/10.1158/1078-0432.CCR-11-0995
Published: 31 October 2011
View article titled, Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group
Open the PDF for Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group in another window
Journal Articles

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

Min H. Kang, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1126–1132.
https://doi.org/10.1158/1078-0432.CCR-08-0144
Published: 19 February 2009
View article titled, Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Open the PDF for Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy in another window
Journal Articles

Molecular Characterization of the Pediatric Preclinical Testing Panel

Geoffrey Neale, Xiaoping Su, Christopher L. Morton, Doris Phelps, Richard Gorlick, Richard B. Lock, C. Patrick Reynolds, John M. Maris, Henry S. Friedman, Jeffrey Dome, Joseph Khoury, Timothy J. Triche, Robert C. Seeger, Richard Gilbertson, Javed Khan, Malcolm A. Smith, Peter J. Houghton
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4572–4583.
https://doi.org/10.1158/1078-0432.CCR-07-5090
Published: 15 July 2008
View article titled, Molecular Characterization of the Pediatric Preclinical Testing Panel
Open the PDF for Molecular Characterization of the Pediatric Preclinical Testing Panel in another window
Includes: Supplementary data
Journal Articles

Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity

Theresa M. Harned, Ondrej Kalous, Alexander Neuwelt, Jason Loera, Lingyun Ji, Peter Iovine, Richard Sposto, Edward A. Neuwelt, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 533–540.
https://doi.org/10.1158/1078-0432.CCR-06-2289
Published: 25 January 2008
View article titled, Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity
Open the PDF for Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity in another window
Journal Articles

Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex

Barry J. Maurer, Ondrej Kalous, David W. Yesair, Xiaqin Wu, Jitka Janeba, Vanessa Maldonado, Vazgen Khankaldyyan, Tomas Frgala, Bee-Chun Sun, R. Travis McKee, Stephen W. Burgess, Walter A. Shaw, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (10): 3079–3086.
https://doi.org/10.1158/1078-0432.CCR-06-1889
Published: 15 May 2007
View article titled, Improved Oral Delivery of <em>N</em>-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex
Open the PDF for Improved Oral Delivery of <em>N</em>-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex in another window
Journal Articles

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini, Jacek Gan, Adam G. Sternberg, Jens Eickhoff, Robert C. Seeger, Katherine K. Matthay, C. Patrick Reynolds, Clare Twist, Mark Krailo, Peter C. Adamson, Ralph A. Reisfeld, Stephen D. Gillies, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1750–1759.
https://doi.org/10.1158/1078-0432.CCR-05-2000
Published: 21 March 2006
View article titled, A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
Open the PDF for A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group in another window
Journal Articles

Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent

Bo Yang, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (7): 2774–2780.
https://doi.org/10.1158/1078-0432.CCR-04-2382
Published: 06 April 2005
View article titled, Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent
Open the PDF for Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent in another window
Journal Articles

Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53

Nino Keshelava, Denice Tsao-Wei, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3492–3502.
Published: 05 September 2003
View article titled, Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53
Open the PDF for Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53 in another window
Journal Articles

Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, Malcolm A. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3646–3657.
Published: 01 December 2002
View article titled, Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle>
Open the PDF for Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle> in another window
Journal Articles

Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium

Nancy D. Doolittle, Lauren E. Abrey, Nicolay Ferrari, Walter A. Hall, Edward R. Laws, Roger E. McLendon, Leslie L. Muldoon, David Peereboom, Darryl R. Peterson, C. Patrick Reynolds, Peter Senter, Edward A. Neuwelt
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (6): 1702–1709.
Published: 01 June 2002
View article titled, Targeted Delivery in Primary and Metastatic Brain Tumors: <subtitle>Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium</subtitle>
Open the PDF for Targeted Delivery in Primary and Metastatic Brain Tumors: <subtitle>Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium</subtitle> in another window
Journal Articles

Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors

Yinglin Wang, Peggy Einhorn, Timothy J. Triche, Robert C. Seeger, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (2): 551–558.
Published: 01 February 2000
View article titled, Expression of <em>Protein Gene Product 9.5</em> and <em>Tyrosine Hydroxylase</em> in Childhood Small Round Cell Tumors
Open the PDF for Expression of <em>Protein Gene Product 9.5</em> and <em>Tyrosine Hydroxylase</em> in Childhood Small Round Cell Tumors in another window